Introduction: Melanoma is a highly aggressive form of skin cancer. While immune checkpoint inhibitors, such as anti-PD-1, are effective, the responses among patients vary significantly. Therefore, complementary therapeutic strategies are needed. Cold atmospheric plasma (CAP), which generates reactive species, can influence the tumor microenvironment, oxidative stress, and angiogenesis. This study examined the effects of CAP, alone and in combination with anti-PD-1, on the expression of
EGFR and
GJA1 in a murine melanoma model.
Materials and Methods: B16-F10 melanoma cells were injected subcutaneously into female C57BL/6 mice. After tumor formation, the animals were divided into five treatment groups: control, CAP, anti-PD-1, CAP + anti-PD-1, and dacarbazine. At the endpoint, tumor tissues were collected, and the mRNA levels of
EGFR and
GJA1 were quantified using RT-qPCR.
Results and Discussion: The CAP + anti-PD-1 combination resulted in a significantly greater downregulation of
EGFR and
GJA1expression compared to the monotherapies, indicating a synergistic effect between the two treatments. Considering that
EGFR promotes angiogenesis and
GJA1 modulates cellular redox signaling and intercellular communication, the combination therapy appears to exert a strong inhibitory effect on these pathways.
Conclusion: Our findings suggest that CAP-based combination therapy could serve as a promising strategy for enhancing the efficacy of immunotherapy in melanoma.